Daniel J.  Brennan net worth and biography

Daniel Brennan Biography and Net Worth

Daniel J. Brennan is our executive vice president and chief financial officer, a position he has held since January 2014. In this role, he is responsible for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development. Prior to that, he was the Company’s senior vice president and corporate controller, a role he served in since January 2010. Since joining Boston Scientific in December 1996, Mr. Brennan has held roles with increased responsibilities, including vice president and assistant corporate controller, vice president of finance and information technology for worldwide financial and strategic planning, investor relations, international finance and Cardiovascular, group controller of the non-vascular business and controller of the Meditech Vascular business. Mr. Brennan is also the Co-Chair of our Global Council for Inclusion. He holds a B.S. degree in Finance and Investments and an M.B.A from Babson College. Mr. Brennan is also a certified public accountant and a member of the College Advisory Board of Babson College. He currently is a member of the board of directors of Nuance Communications.

What is Daniel J. Brennan's net worth?

The estimated net worth of Daniel J. Brennan is at least $24.44 million as of February 20th, 2024. Mr. Brennan owns 271,542 shares of Boston Scientific stock worth more than $24,438,780 as of November 23rd. This net worth approximation does not reflect any other investments that Mr. Brennan may own. Additionally, Mr. Brennan receives a salary of $2,150,000.00 as CFO at Boston Scientific. Learn More about Daniel J. Brennan's net worth.

How old is Daniel J. Brennan?

Mr. Brennan is currently 58 years old. There are 7 older executives and no younger executives at Boston Scientific. The oldest executive at Boston Scientific is Mr. David J. Roux, Independent Director, who is 67 years old. Learn More on Daniel J. Brennan's age.

What is Daniel J. Brennan's salary?

As the CFO of Boston Scientific Co., Mr. Brennan earns $2,150,000.00 per year. The highest earning executive at Boston Scientific is Mr. Michael F. Mahoney, Chairman, President & CEO, who commands a salary of $4,830,000.00 per year. Learn More on Daniel J. Brennan's salary.

How do I contact Daniel J. Brennan?

The corporate mailing address for Mr. Brennan and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at [email protected]. Learn More on Daniel J. Brennan's contact information.

Has Daniel J. Brennan been buying or selling shares of Boston Scientific?

Daniel J. Brennan has not been actively trading shares of Boston Scientific during the past quarter. Most recently, Daniel J. Brennan sold 13,662 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a transaction totalling $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares of the company's stock, valued at $17,883,756.12. Learn More on Daniel J. Brennan's trading history.

Who are Boston Scientific's active insiders?

Boston Scientific's insider roster includes Kevin Ballinger (EVP), Supratim Bose (EVP), Daniel Brennan (CFO), Vance Brown (SVP), Arthur Butcher (EVP), Wendy Carruthers (SVP), Nelda Connors (Director), Keith Dawkins (EVP), Charles Dockendorff (Director), Jodi Eddy (SVP), Joseph Fitzgerald (EVP), Edward Ludwig (Director), Edward Ludwig (Director), Edward Mackey (EVP), Michael Mahoney (CEO), Ian Meredith (EVP), Jeffrey Mirviss (EVP), Jonathan Monson (CAO), Maulik Nanavaty (SVP), Scott Olson (SVP), Michael Phalen (EVP), David Pierce (EVP), Timothy Pratt (EVP), Desiree Ralls-Morrison (SVP), Meghan Scanlon (SVP), John Sorenson (SVP), Eric Thepaut (EVP), Xin Wang (SVP), and David Wichmann (Director). Learn More on Boston Scientific's active insiders.

Are insiders buying or selling shares of Boston Scientific?

During the last twelve months, insiders at the medical equipment provider sold shares 22 times. They sold a total of 486,553 shares worth more than $38,417,686.88. The most recent insider tranaction occured on November, 21st when Director Edward J Ludwig sold 4,877 shares worth more than $446,879.51. Insiders at Boston Scientific own 0.5% of the company. Learn More about insider trades at Boston Scientific.

Information on this page was last updated on 11/21/2024.

Daniel J. Brennan Insider Trading History at Boston Scientific

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2024Sell13,662$65.86$899,779.32271,542View SEC Filing Icon  
3/1/2023Sell75,610$46.64$3,526,450.40255,958View SEC Filing Icon  
2/15/2023Sell7,572$47.14$356,944.08276,316View SEC Filing Icon  
2/22/2022Sell53,182$42.75$2,273,530.50View SEC Filing Icon  
2/16/2022Sell12,187$43.70$532,571.90View SEC Filing Icon  
2/23/2021Sell24,846$39.23$974,708.58
1/5/2021Sell17,083$35.32$603,371.56263,243View SEC Filing Icon  
2/13/2020Sell20,463$42.03$860,059.89250,710View SEC Filing Icon  
10/2/2019Sell20,462$39.44$807,021.28235,422View SEC Filing Icon  
3/14/2019Sell46,360$40.02$1,855,327.20214,960View SEC Filing Icon  
3/4/2019Sell64,223$40.84$2,622,867.32View SEC Filing Icon  
2/14/2019Sell22,438$39.57$887,871.66279,183View SEC Filing Icon  
3/19/2018Sell60,209$27.87$1,678,024.83299,644View SEC Filing Icon  
7/11/2017Sell92,158$27.48$2,532,501.84235,421View SEC Filing Icon  
2/25/2016Sell103,211$17.22$1,777,293.42202,659View SEC Filing Icon  
See Full Table

Daniel J. Brennan Buying and Selling Activity at Boston Scientific

This chart shows Daniel J Brennan's buying and selling at Boston Scientific by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Boston Scientific Company Overview

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $90.00
Low: $89.02
High: $91.93

50 Day Range

MA: $85.99
Low: $82.52
High: $91.54

2 Week Range

Now: $90.00
Low: $53.93
High: $91.93

Volume

5,419,721 shs

Average Volume

6,077,987 shs

Market Capitalization

$132.64 billion

P/E Ratio

74.38

Dividend Yield

N/A

Beta

0.79